| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Seer, Inc.$2.17
0 (-0.15%)
D 32Pipeline Score Tools & Services · Clinical
Market Cap
98.42 M
EPS
-1.24
P/E Ratio
-
Value Trade
105.81 K
SEC Financials
Q1 2026Dilution Risk
Revenue
2.79 M
R&D Expenses
8.81 M
Operating CF
-15.44 M
Total Assets
272.13 M
Total Liabilities
30.65 M
Equity
241.48 M
D/E Ratio
12,345
2.29 %
Week
-10.95 %
1 Month
-15.17 %
3 Month
-8.21 %
6 Month
-93.81 %
5 Year
-96.27 %
All Time
Cash Data
Cash Position
166.67 M
Monthly Burn
5.14 M
Runway
30.7 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
301.33 K
52 Week Range
1.65 - 2.41
% held by Insiders
34.58 %
% held by Institutions
23.46 %
Enterprise Value
-45.23 M
Total Shares
56.46 M
Short %
0.38 %
Float Shares
34.61 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D32
Pipeline Score $9M
Pipeline ValueValuation Signal
1
Drugs Scored0.1x
rNPV / MCap Top 39%
Micro Cap (rank 557 of 911)
Percentile RankSeer, Inc. faces pipeline headwinds (32/100), with $176M risk-adjusted pipeline value, led by standardized turmeric root extract in Cystic Fibrosis (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| standardized turmeric root extract Small molecule | Cystic Fibrosis | Phase 1 | NCT00219882 | 9% | $176M | COMPLETED | 11 | - | - | Jan 1, 2006 | - | Dec 25, 2007 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SEER
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SEER Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SEERThe Radoff-JEC Group Urges Seer, Inc. Stockholders to Vote for Boardroom Change Today
The Radoff-JEC Group is calling on Seer, Inc. stockholders to support a change in the boardroom. However, the article provides minimal details about the motivations for this request or the implications of such a change. The lack of information may leave stockholders uncertain about the situation.
Read more →SEERThe Radoff-JEC Group Highlights Seer Inc.’s and Chairman and CEO Omid Farokhzad, M.D.’s History of Value Destruction
The article discusses the Radoff-JEC Group's focus on Seer Inc. and its leadership under Omid Farokhzad, M.D. It emphasizes a history of value destruction linked to the company, raising concerns about its management and strategic direction. The analysis suggests a critical view of the company's performance.
Read more →SEERSeer Board of Directors Issues Letter to Shareholders Highlighting the Company’s Significant Scientific Progress and Addressing Radoff and Torok’s Short-Sighted Campaign
Seer, Inc. has issued a letter to shareholders urging support for its board of directors ahead of the Annual Meeting on July 28, 2026. The letter highlights Seer's advancements in proteomics technology, significant growth in scientific validation, and disciplined financial management. The board recommends voting for its nominees against activist shareholders who propose undervalued acquisitions. The company emphasizes its commitment to long-term value creation.
Read more →SEERSeer Files Definitive Proxy Materials and Mails Letter to Stockholders
Seer, Inc. has filed definitive proxy materials for its upcoming Annual Meeting, urging stockholders to vote for its director nominees. The company emphasizes its strong governance and strategic direction while criticizing activist stockholders Radoff and Torok for their disruptive campaign. Seer highlights its progress in proteomics technology and the importance of maintaining its current board to ensure long-term value creation.
Read more →SEERSeer Files ITC Complaint Against Nanomics
Seer, Inc. has filed a complaint against Nanomics Biotechnology at the ITC, claiming patent infringement related to nanoparticle protein enrichment technologies. This action follows a federal district court lawsuit initiated earlier in May 2026. Seer aims to prevent the importation of Nanomics' products and protect its proprietary technology. The complaint is supported by Brigham and Women's Hospital.
Read more →SEERThe Radoff-JEC Group Calls on Seer Inc. and Its Advisors to Reevaluate Its Premium Acquisition Proposal in the Best Interests of All Stockholders
The Radoff-JEC Group has urged Seer Inc. and its advisors to reconsider their premium acquisition proposal. The group believes that the current proposal may not serve the best interests of all stockholders. This call for reevaluation highlights potential concerns regarding the adequacy of the offer.
Read more →SEERSeer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026
Seer, Inc. will showcase its AI-driven multi-cancer screening and next-generation proteomics at the ASMS 2026 conference. The company will present findings from collaborations, including a large-scale study analyzing over 20,000 clinical plasma samples. Seer aims to demonstrate the capabilities of its Proteograph platform in advancing biomarker discovery and precision medicine.
Read more →SEER▲ +5.4%on this newsshared move
Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group
Seer, Inc.'s Board of Directors has unanimously rejected a revised unsolicited acquisition proposal from the Radoff-JEC Group, citing that it undervalues the company. The proposal, which offers $2.40 per share, was deemed not in the best interests of Seer stockholders. This rejection follows a similar proposal that was turned down earlier in April 2026.
Read more →SEERThe Radoff-JEC Group Submits its Third Non-Binding Proposal to Acquire Seer, Inc.
The Radoff-JEC Group has submitted its third non-binding proposal to acquire Seer, Inc. This proposal indicates ongoing interest in Seer, although details about the offer or its implications are not provided. The situation remains fluid as negotiations may continue.
Read more →SEERSeer Files Patent Infringement Lawsuit Against Nanomics
Seer, Inc. has filed a patent infringement lawsuit against Nanomics Biotechnology, asserting multiple patents related to nanoparticle protein enrichment. The lawsuit aims to protect Seer's intellectual property, which is crucial for its Proteograph® Product Suite. Seer seeks monetary damages and injunctive relief, emphasizing the importance of its innovations in the field of proteomics.
Read more →SEERSeer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook
Seer, Inc. reported its financial results for Q1 2026, achieving $2.8 million in revenue, a 34% decline from the previous year. The company secured a significant collaboration for a large-scale proteomics study and appointed a new Chief Commercial Officer. Despite these advancements, Seer faced a net loss of $16.8 million amid a challenging funding environment.
Read more →SEERSeer Announces Appointment of Anthony Bazarko as Chief Commercial Officer
Seer, Inc. has appointed Anthony Bazarko as Chief Commercial Officer to enhance its commercial strategy and growth. Bazarko, with extensive experience in life sciences and biotechnology, aims to expand the adoption of Seer's Proteograph® Product Suite. His previous roles include leadership positions at Biologos and Specific Diagnostics, where he successfully drove revenue and strategic initiatives.
Read more →SEERSeer to Report First Quarter 2026 Financial Results on May 13, 2026
Seer, Inc. has announced that it will report its financial results for the first quarter of 2026 on May 13, 2026. The company will hold a conference call at 1:30 p.m. Pacific Time, which will be webcast live. Seer's Proteograph Product Suite is recognized for its advanced capabilities in proteomics.
Read more →SEERThe Radoff-JEC Group Responds to Seer, Inc.’s Rejection of April 24th Acquisition Proposal
The Radoff-JEC Group, holding approximately 7.6% of Seer, Inc.'s shares, has responded to the company's Board of Directors' rejection of their acquisition proposal. The proposal included an offer of $2.35 per share in cash along with a contingent value right. The rejection indicates the Board's decision against the acquisition at this time.
Read more →SEERSeer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group
Seer, Inc.'s Board of Directors has unanimously rejected a revised unsolicited acquisition proposal from the Radoff-JEC Group, citing that it significantly undervalues the company. The Board emphasized Seer's compelling growth potential and strategic position in the proteomics market. They believe the proposal does not adequately reflect Seer's current assets or future opportunities.
Read more →SEERThe Radoff-JEC Group Submits Improved Non-Binding Proposal to Acquire Seer, Inc.
The Radoff-JEC Group has submitted an improved non-binding acquisition proposal for Seer, Inc. at $2.35 per share, representing a 39% premium. The proposal aims to address Seer's significant losses and lack of revenue growth under current management. The group expresses skepticism about Seer's viability as an independent company, citing poor performance compared to industry peers.
Read more →SEER▲ +13.6%on this news
The Radoff-JEC Group Submits Non-Binding Proposal to Acquire Seer, Inc.
The Radoff-JEC Group has submitted a non-binding proposal to acquire Seer, Inc. Details regarding the proposal or the implications for Seer, Inc. have not been disclosed. The announcement comes amid ongoing interest in the biopharma sector. Further developments are expected as the situation unfolds.
Read more →SEER▲ +13.6%on this news
Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group No Stockholder Action Required at This Time REDWOOD CITY, Calif. –
Seer, Inc. has confirmed the receipt of a non-binding, unsolicited acquisition proposal from the Radoff-JEC Group, offering $2.25 per share for all outstanding Class A common stock. The company's Board of Directors will review this proposal in consultation with their financial and legal advisors. Additionally, the Radoff-JEC Group has nominated three candidates for election to the Board at the upcoming 2026 Annual Meeting. Currently, no stockholder action is required regarding these matters.
Read more →SEERSeer and Precision Health Research, Singapore Sign Collaboration to Provide Deep, Unbiased Proteomics on 10,000 PRECISE SG100K Samples
Seer, Inc. has partnered with Precision Health Research in Singapore to utilize its Proteograph Product Suite for profiling the plasma proteome of 10,000 participants from the PRECISE-SG100K study. This collaboration aims to integrate genomic and proteomic data to advance precision health and disease prevention. The project is expected to yield significant insights into health outcomes and disease risk in diverse populations.
Read more →SEERPatent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries
Seer, Inc. announced that the U.S. Patent Trial and Appeal Board upheld 23 claims of its '360 Patent, which covers methods for analyzing biological samples using engineered nanoparticles. This decision reinforces the validity of Seer's Proteograph platform, essential for deep proteomic analysis. Seer plans to continue protecting its intellectual property and advancing its technology.
Read more →SEERThe Radoff-JEC Group Sends Open Letter to Seer, Inc. Unconflicted Independent Directors Meeta Gulyani and Nicolas Roelofs
The Radoff-JEC Group, owning 7.6% of Seer, Inc., has expressed dissatisfaction with the company's Board and management. They criticize the leadership for poor financial performance and governance, highlighting a significant cash burn and minimal revenue growth. The group is urging independent directors to act in the best interest of stockholders and consider a sale process for the company.
Read more →SEERSeer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook
Seer, Inc. has reported its financial results for Q4 and the full year 2025. Revenue for the fourth quarter was $4.2 million, reflecting a 5% increase compared to the prior year, while the full-year revenue reached $16.6 million, marking a 17% increase. Despite the financial upswing, the company reported a net loss of $16.0 million for Q4 2025, though this represents an improvement from $21.7 million in the same period last year. The company anticipates revenue growth for 2026, projecting figures between $16 million and $18 million.
Read more →SEERSeer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets
Seer, Inc. has adopted a tax benefit preservation plan aimed at protecting its valuable net operating loss carryforwards, amounting to approximately $262 million. This initiative seeks to prevent impairment from significant stock ownership changes and will be submitted for ratification to shareholders at the upcoming 2026 annual meeting. The plan includes mechanisms to limit shareholders from acquiring more than 4.9% of the Class A common stock without board approval. If shareholders do not ratify the plan, it will have a shorter duration than initially intended.
Read more →SEERSeer to Participate in the TD Cowen 46th Annual Health Care Conference
Seer, Inc. (Nasdaq: SEER) announced its participation in the TD Cowen 46th Annual Health Care Conference in Boston, MA, where management will engage in a fireside chat. This event is set for March 4, 2026, with a live webcast available for investors. Seer, a leader in deep proteomics, aims to provide advanced insights that surpass traditional proteomic methods. The company’s products are intended for research purposes only and not for diagnostics.
Read more →SEERSeer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Seer, Inc. announced it will report its financial results for Q4 and full year 2025 on February 26, 2026. The company will host a conference call at 1:30 p.m. PT, which will be available via webcast. Seer is known for its Proteograph Product Suite, aimed at advancing proteomic analysis.
Read more →SEERNature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers
Seer, Inc. announced the publication of a significant genome-wide association study in Nature Genetics, validating its Proteograph platform's role in accurately identifying drug targets and biomarkers. The study demonstrated that mass spectrometry is essential for confirming protein-gene associations, revealing that many findings from traditional methods may be inaccurate. This research underscores the importance of peptide-level validation in proteomics for reliable drug discovery and biomarker development.
Read more →SEERSeer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025
Seer, Inc. presented new data at the HUPO World Congress 2025, highlighting the transformative impact of its Proteograph Product Suite on proteomics research. The findings emphasize the platform's role in advancing studies across cardiovascular, oncology, and aging biology. Seer's participation includes numerous scientific presentations, showcasing the scalability and clinical relevance of their technology.
Read more →SEERSeer Reports Third Quarter 2025 Financial Results
Seer, Inc. reported its third quarter 2025 financial results, highlighting a 2% revenue increase to $4.1 million, driven by strong demand for its Proteograph ONE workflow. The company achieved a record number of third-party publications supporting its technology. However, it still faced a net loss of $18.2 million despite a reduction in operating expenses. Seer anticipates full-year revenue growth of 24% over 2024.
Read more →SEERSeer to Participate in Upcoming November Investor Conferences
Seer, Inc. announced its participation in several investor conferences scheduled for November. The company, known for its advancements in proteomics, will provide live webcasts of the sessions on its investor website. Seer's Proteograph Product Suite is noted for delivering unmatched proteomic insights, emphasizing the company's leadership in the field.
Read more →SEERSeer to Report Third Quarter 2025 Financial Results on November 6, 2025
Seer, Inc. has announced it will release its financial results for the third quarter of 2025 on November 6, 2025. The announcement includes details of a conference call that will be webcasted at 1:30 p.m. Pacific Time. Seer highlights its advancements in proteomics, emphasizing the speed and precision of its innovative technologies, which are designed to overcome the limitations of traditional methods. The company positions itself as a leader in delivering deep, unbiased proteomic insights.
Read more →SEERSeer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025
Seer, Inc. will participate in the ASHG 2025 Annual Meeting, showcasing how proteomics complements genomics in advancing precision medicine. The company will host a CoLab session and feature multiple scientific presentations demonstrating the capabilities of its Proteograph Product Suite. This event reflects the growing significance of proteomics in understanding disease biology and enhancing clinical research.
Read more →SEERSeer Appoints Isaac Ro to its Board of Directors
Seer, Inc. has appointed Isaac Ro to its Board of Directors, bringing extensive experience in life sciences and finance. Ro's background includes leadership roles in various successful companies, which will aid Seer in achieving its growth milestones. The company aims to advance its innovative proteomic platform under Ro's guidance.
Read more →SEERSeer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Seer, Inc. announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will engage in a fireside chat on September 9, 2025. A live webcast of the event will be available on Seer's investor website, with an archived replay to follow. Seer continues to lead in deep proteomic insights.
Read more →SEERSeer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
Seer, Inc. reported a 32% year-over-year revenue increase for Q2 2025, reaching $4.1 million. The company launched the Proteograph ONE assay and SP200 automation instrument, enhancing its proteomics platform. Despite a net loss of $19.4 million, Seer expects full-year revenue to grow by 24% compared to 2024. Operating expenses decreased significantly, contributing to improved financial metrics.
Read more →SEERSeer to Participate in the Canaccord Genuity 45th Annual Growth Conference
Seer, Inc. will participate in the Canaccord Genuity 45th Annual Growth Conference in Boston. The management team is scheduled for a fireside chat on August 13, 2025, at 9:00 a.m. ET. A live webcast will be available on their investor website, with an archived replay following the event.
Read more →SEERSeer to Report Second Quarter 2025 Financial Results on August 6, 2025
Seer, Inc. has announced it will report its financial results for the second quarter of 2025 on August 6, 2025. The company will host a conference call at 1:30 p.m. PT to discuss these results, which will be available via webcast. Seer is recognized for its innovative approach in proteomics, providing insights that surpass traditional methods.
Read more →SEER▲ +11.5%on this news
Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
Seer, Inc. has partnered with Korea University to launch a groundbreaking study aimed at identifying blood-based biomarkers for early cancer detection in young adults using their Proteograph ONE Assay. This initiative is the first of its kind to conduct mass proteomic analysis on 20,000 plasma samples. The three-year study, funded by the K-Health MIRAE initiative, leverages advanced technology to enhance the accuracy and speed of diagnostics, potentially transforming cancer management. The collaboration showcases the innovative application of AI in developing precise medical diagnostics.
Read more →SEERSeer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency
Seer, Inc. has launched its new Proteograph Product Suite, including the Proteograph ONE Assay and SP200 Automation Instrument, aimed at improving the scalability and efficiency of deep proteomic studies. Unveiled at the ASMS 2025 conference, the solution enhances throughput to over 1,000 samples per week and decreases costs by approximately 60% compared to previous offerings. This innovation sets the stage for population-scale proteomic research, potentially transforming advancements in personalized medicine and biomarker discovery. The launch is seen as a milestone in overcoming traditional barriers in proteomic analysis.
Read more →SEERSeer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook Revenue grew 37%, driven by increased product sales and service revenue
Seer, Inc. has reported a strong financial performance for the first quarter of 2025, with a revenue growth of 37% driven by increased product sales and service revenue, amounting to $4.2 million. The company secured a significant contract for a 10,000-sample study, affirming its market position. Despite these positive indicators, Seer recorded a net loss of $19.9 million and cautioned that it expects continuing volatility due to external economic factors. Seer also reiterated its full-year revenue outlook of $17 million to $18 million, representing a growth of approximately 24% over the previous year.
Read more →SEERSeer to Report First Quarter 2025 Financial Results on May 13, 2025
Seer, Inc. has announced it will report its financial results for the first quarter of 2025 on May 13, 2025. The company will host a webcast for investors starting at 1:30 p.m. PT. Seer is recognized for its disruptive Proteograph Product Suite, which combines advanced technology for scalable proteomic analysis. The solutions offered are not for diagnostic use, but serve a crucial role in research laboratories.
Read more →SEERSEER LAUNCHES CARBON FOCUSED DIVISION TO PRODUCE LICENSED BIOCHAR, MONETIZE AND TOKENIZE ASSETS AND CARBON CREDITS AND DEVELOP TURBINE BLADE TREATMENT TECHNOLOGY
Strategic Environmental & Energy Resources, Inc. (SEER) has announced the formation of SEER Carbon Corp., aiming to produce biochar and generate robust carbon credits. This initiative leverages patented technologies and strategic partnerships to create high-quality carbon credits that will be sold internationally. The biochar market shows promising growth prospects, with projections indicating a significant increase in credits by 2028. SEER's approach includes addressing quality concerns in the biochar market, ensuring sustainable and valuable environmental offerings.
Read more →SEERSeer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook Validated technology with exceptional growth of customer publications and enhanced access to the Proteograph Product Su
Seer, Inc. reported its financial results for the fourth quarter and full year of 2024, revealing a 15% decrease in total revenue compared to 2023, with a net loss of $86.6 million. Despite these challenges, Seer showcased growth in customer publications and a successful launch of the Proteograph XT workflow. The company ended 2024 with approximately $300 million in cash and expects revenue growth for 2025 in the range of $17 million to $18 million. CEO Omid Farokhzad expressed confidence in Seer's technology and growth trajectory, highlighting the increased demand for its Proteograph Product Suite.
Read more →SEERSeer to Participate in the TD Cowen 45th Annual Health Care Conference
Seer, Inc. has announced its participation in the TD Cowen 45th Annual Healthcare Conference to be held in Boston, MA. The company's management will be engaged in a fireside chat scheduled for March 4th. Seer's innovative Proteograph™ Product Suite promises transformative solutions in proteomic analysis, emphasizing ease of use and efficiency. This engagement at the conference showcases Seer's growing presence in the life sciences sector.
Read more →SEERSeer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
Seer, Inc. will present significant advancements in proteomics at the US HUPO 2025 Conference, including a novel therapeutic platform that targets cancer vulnerabilities. The company highlights its Proteograph Product Suite, which enables deep cellular proteomics studies and improvements in cancer treatment approaches. Key presentations will detail innovative applications in both cancer and cardiometabolic research. The upcoming seminar, led by Dr. Jinjun Shi, will discuss groundbreaking findings in prostate cancer treatment.
Read more →SEERSeer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Seer, Inc. has announced that it will report its financial results for the fourth quarter and full year of 2024 on February 27, 2025. The company is known for its groundbreaking work in proteomics, specifically with its Proteograph™ Product Suite, which is designed for deep proteomic analysis. A live webcast of the conference call will be available, with an archived replay accessible on the company's website afterward. This event could provide insights into the company’s recent performance and future direction in the life sciences sector.
Read more →SEERSeer to Present at the J.P. Morgan 43rd Annual Healthcare Conference
Seer, Inc. has announced its participation in the J.P. Morgan 43rd Annual Healthcare Conference scheduled for January 15, 2025. The company's management will present and hold a Q&A session, with a live webcast available. Seer is recognized for its transformative Proteograph Product Suite, which enables deep proteomic analysis efficiently. The event emphasizes Seer’s innovative work in the life sciences sector.
Read more →SEERSEER AND ECO TADWEER SHOWCASE SIGNIFICANT ACHIEVEMENTS IN THE KINGDOM OF SAUDI ARABIA WITH MULTIPLE BIOCHAR APPLICATIONS AND GROW STUDIES
SEER, alongside its partner Eco Tadweer, has reported significant advancements in the Green Riyadh Project, supporting Saudi Arabia's environmental goals. The collaboration has yielded promising results in biochar applications to enhance soil and plant health. SEER aims to transform these early successes into profitable contracts while promoting sustainable agriculture and water management practices. The project reflects a commitment to decarbonization and generating verifiable carbon credits under Saudi Arabia's green initiatives.
Read more →SEERSEER PARTNERS WITH DEVVSTREAM TO MONETIZE INSURED CARBON CREDITS ARISING OUT OF METHANE RENEWABLE ENERGY, CAPTURED OIL FIELD WELL EMISSIONS AND OTHER SEER PROJECTS
SEER has announced a strategic partnership with DevvStream to develop a comprehensive program focused on carbon credit monetization from various environmental projects. This collaboration aims to utilize SEER's cutting-edge technologies, including biogas capture and oil field emission reduction technologies, to quantify and monetize high-quality carbon credits. The partnership comes at a time when the carbon credit market is expected to grow significantly. SEER's experiences with early projects, including those in Saudi Arabia, further bolster their potential in the carbon credit space.
Read more →SEERSeer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Seer, Inc. has been recognized as the 57th fastest-growing company on the 2024 Deloitte Technology Fast 500, boasting an impressive revenue growth of 2,440% over the past three years. The growth has been attributed to the rising adoption of its Proteograph Product Suite and new discoveries related to neurodegenerative and metabolic diseases. Additionally, the company has launched a technology access center in Europe and entered into a co-marketing agreement with Thermo Fisher Scientific. Previously, Seer ranked No. 5 in the same Deloitte list for 2023.
Read more →SEERSeer Reports Third Quarter 2024 Financial Results
Seer, Inc. reported its financial results for the third quarter of 2024, highlighting a revenue of $4.0 million, a slight decrease from the previous year. The company entered a co-marketing agreement with Thermo Fisher Scientific to enhance sales and access to its Proteograph Product Suite. Despite presenting innovations at the HUPO World Congress, Seer also noted a net loss of $21.3 million for the quarter. The company ended the period with approximately $312 million in cash and investments, maintaining expectations for full-year revenue between $13 to $15 million.
Read more →SEERSeer Reports Third Quarter 2024 Financial Results Growing enthusiasm for Proteograph Product Suite with multiple larger orders from government agencies and continued strong interest in
Seer, Inc. reported its third quarter 2024 financial results, revealing a revenue of $4.0 million. The company highlighted growing demand for its Proteograph Product Suite and established a significant partnership with Thermo Fisher Scientific. Despite a decrease in revenue compared to the prior year, Seer remains optimistic about its future potential, boasting a strong cash reserve of approximately $312 million. The net loss increased slightly to $21.3 million, raising concerns amid otherwise positive developments.
Read more →SEERSeer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
Seer, Inc. has announced a co-marketing and sales agreement with Thermo Fisher Scientific to promote Seer's Proteograph Product Suite in conjunction with Thermo Fisher's Orbitrap Astral mass spectrometers. This strategic move aims to increase the adoption of proteomic technologies, providing researchers with an integrated solution for thorough analysis. The collaboration will facilitate joint marketing and research initiatives, enhancing workflow and accessibility for life science researchers. The integration is scheduled to begin in early 2025.
Read more →SEERSeer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
Seer, Inc. is set to showcase its Proteograph Product Suite at the ASHG 2024 Annual Meeting, emphasizing its role in enhancing genomic insights through deep proteomics. The company will present collaborative research focused on various diseases, including Alzheimer’s and lung cancer. One significant highlight is a study on early detection of lung cancer using a multi-omics biomarker test that shows promise in identifying the disease at earlier stages. Additionally, insights into Relative Energy Deficiency in Sport (REDs) will be explored, emphasizing the importance of understanding this condition at a molecular level.
Read more →SEERSeer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024
Seer, Inc. presented major advancements in proteomics at the HUPO 2024 World Congress in Germany. Their Proteograph Product Suite is notable for enabling large-scale and in-depth proteomic research, particularly relevant in fields such as Alzheimer's disease and population health. Notable studies showcased include the correlation between genetic variants and Alzheimer's, as well as innovative methods for population-scale plasma proteomics. The company also highlighted its role in advancing xenotransplantation research through ultra-deep longitudinal profiling of serum proteins.
Read more →SEERSeer to Report Third Quarter 2024 Financial Results on November 6, 2024
Seer, Inc., a life sciences company based in Redwood City, announced its plans to report third quarter 2024 financial results on November 6, 2024. The company will host a webcasting conference call to discuss these results. Seer's innovative Proteograph Product Suite aims to improve proteomic analysis, making it more efficient and accessible for laboratories. The event will be accessible live and recorded for later viewing on their website.
Read more →SEERSeer Appoints Nicolas Roelofs to its Board of Directors
Seer, Inc. has appointed Dr. Nicolas Roelofs to its Board of Directors as the company aims to capitalize on its innovative proteomics platform. Dr. Roelofs brings over 35 years of experience in the life sciences sector, having held senior roles at multiple leading organizations. His expertise is expected to aid in accelerating the adoption of Seer’s Proteograph Product Suite, which offers advanced proteomic analysis capabilities. This strategic move highlights Seer’s commitment to advancing its mission in the proteomics field.
Read more →SEERSeer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Seer, Inc. has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City, scheduled for September 5th. The company's management will engage in a fireside chat, which can be viewed live via a webcast. This event highlights Seer’s advancements in proteomics through its Proteograph Product Suite, designed to provide in-depth proteomic analysis efficiently. The Proteograph suite represents a significant development aimed at transforming research capabilities in life sciences.
Read more →SEERSeer to Participate in the Canaccord Genuity 44th Annual Growth Conference
Seer, Inc. will participate in the Canaccord Genuity 44th Annual Growth Conference in Boston, scheduled for August 14, 2024. The company's management will engage in a fireside chat, part of the event’s agenda. Seer is known for its Proteograph Product Suite, which facilitates advanced proteomic analysis. The session will be available via live webcast and later as an archived replay on Seer’s website.
Read more →SEERSeer Reports Second Quarter 2024 Financial Results Launched STAC in Europe and additional customer papers published in leading journals
Seer, Inc. reported its financial results for Q2 2024, indicating a revenue of $3.1 million, a decline of 23% from the previous year. The company has launched its Seer Technology Access Center (STAC) in Europe, which aims to improve access to their Proteograph Product Suite. Despite a cash position of $344.6 million, Seer anticipates full-year revenues to fall between $13 million and $15 million, down from earlier projections. The net loss reported was $22.9 million, slightly improved compared to Q2 2023.
Read more →SEERSEER’S MV TECHNOLOGIES RECEIVES NEW SYSTEM AND MEDIA REPLACEMENT CONTRACTS FOR $1.4MM AND INCREASES RECURRING ANNUAL MEDIA SUPPLY CONTRACTS
SEER's operating company, MV Technologies, has received new contracts totaling approximately $1.4 million for H2S removal systems and media replacements across various industries in the US. This includes a significant $600,000 order from a major potato processor and additional systems placed in the dairy sector. MV's ongoing relationships with key clients have resulted in repeat orders, emphasizing the reliability of their biogas treatment technology. The company anticipates further contracts as it continues to bid on projects throughout North America.
Read more →SEERSeer to Report Second Quarter 2024 Financial Results on August 8, 2024
Seer, Inc. has announced it will report its financial results for the second quarter of 2024 on August 8, 2024. A conference call with company management will be held at 1:30 p.m. PT. The event will be available via webcast for interested investors. Seer continues to innovate in the field of proteomics with its Proteograph Product Suite, designed for efficient and scalable analysis.
Read more →SEERSEER RECEIVES CONTRACT FROM BIOCHAR NOW FOR THE MANUFACTURING OF KILNS AND INTENDS TO OPEN A JV TEXAS BIOCHAR FACILITY
SEER's subsidiary, SEM, LLC, has received a purchase order from Biochar Now for the manufacturing of 33 kilns, valued at approximately $600,000. This contract marks a significant step in SEER's growth strategy, signaling close collaboration with BCN on domestic and international expansion plans. In addition, SEER is planning the establishment of a Texas joint venture facility, which will enhance their capabilities in processing waste materials. The partnership is also focused on international opportunities, indicating future revenue streams for SEER.
Read more →SEERSeer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
Seer, Inc. has announced the publication of three significant studies that utilize its Proteograph Product Suite to uncover proteomic alterations during spaceflight missions. These studies highlight the impact of spaceflight on human physiology and aim to advance precision medicine and biomarker discovery. They include a comprehensive data atlas from multiple space missions and insights from the first all-civilian spaceflight, showing notable changes in proteins related to oxidative stress and coagulation. The findings reinforce the potential of Seer's technology to deepen research into proteomics and genomics.
Read more →SEERSeer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
Seer, Inc. announced that PrognomiQ has completed a groundbreaking study utilizing their Proteograph Product Suite and Thermo Fisher's mass spectrometer. This research involved a cohort of 2,840 subjects, achieving the detection of over 13,000 protein groups in plasma, enhancing early cancer detection methods. The study highlights a significant milestone in cancer biomarker research and showcases the efficacy of collaborative proteomics technologies. Results will be presented at the ASMS Conference on June 6.
Read more →SEERSeer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
Seer, Inc. has announced the opening of the Seer Technology Access Center (STAC) in Bonn, Germany, scheduled for June. This center aims to provide European researchers with access to the Seer Proteograph™ Product Suite and advanced mass spectrometry technologies to facilitate deep, unbiased proteomic studies. The facility, located at Life & Brain GmbH, will accelerate biomarker discovery and drug development processes, addressing a significant need in the biopharma community. With advanced automation and capabilities, the STAC is expected to increase throughput and make proteomics research more accessible.
Read more →SEERSeer Reports First Quarter 2024 Financial Results
Seer, Inc. reported its financial results for the first quarter of 2024, highlighting a revenue of $3.1 million, a decrease from $4.1 million in Q1 2023. The company announced the expansion of its Seer Technology Access Center program to Europe and launched the 2024 Seer Insights Grant Program. Despite achieving some milestones, Seer faced a net loss of $20.7 million and operating expenses stood at $26.6 million. The firm authorized a $25 million share repurchase program to bolster investor confidence.
Read more →SEERSeer Reports First Quarter 2024 Financial Results Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications
Seer, Inc. reported its financial results for the first quarter of 2024, highlighting a revenue of $3.1 million, down 24% from the same period last year. The company launched the Seer Technology Access Center in Europe and validated its Proteograph Product Suite with three peer-reviewed publications. Despite these achievements, Seer posted a net loss of $20.7 million and acknowledged ongoing financial headwinds. The firm aims to enhance its commercial adoption amidst these challenges.
Read more →SEER▲ +8.4%on this news
Seer to Report First Quarter 2024 Financial Results on May 8, 2024
Seer, Inc. has announced its intention to report financial results for the first quarter of 2024 on May 8, 2024. The company, known for its advancements in proteomics, will host a conference call to discuss these results. Interested parties can access the live webcast on Seer's investor website, with an archived replay to be made available afterward. The company continues to focus on developing products that improve proteomic analysis capabilities.
Read more →SEERSeer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data
Seer, Inc. reported its financial results for the fourth quarter and full year 2023, noting an 8% increase in total revenue to $16.7 million. Despite shipping 23 instruments and launching a Protein Discovery Catalog, the company saw a 4% decline in Q4 revenue compared to the previous year, leading to a net loss of $17.8 million. For 2024, Seer projects a revenue range of $18 million to $20 million, indicating expected growth. The company highlighted the importance of its Proteograph Product Suite in advancing proteomic research and acquiring new customers.
Read more →SEERSeer to Participate in the TD Cowen 44th Annual Health Care Conference
Seer, Inc. announced its participation in the TD Cowen 44th Annual Health Care Conference scheduled for March 4th in Boston, MA. The company's management will engage in a fireside chat and Q&A session, which will also be webcast live for investors. Seer is recognized for its Proteograph Product Suite, which offers significant advancements in proteomic analysis. This participation reflects Seer's commitment to showcasing its innovations and engaging with stakeholders in the life sciences sector.
Read more →SEER▲ +6%on this news
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery
Seer, Inc. announced a significant advancement in proteogenomic studies through its Proteograph technology, showcased in a study by Weill Cornell Medicine. The research published in Nature Communications highlights the platform's capability to identify protein-altering variants linked to drug discovery. With the ability to process vast amounts of protein data at peptide level resolution, the Proteograph workflow opens new avenues for precision medicine. Additionally, the recent launch of the Proteograph XT Assay Kit further enhances throughput and resolution in proteomic research, though the company acknowledges inherent challenges in proteomic analysis.
Read more →SEERSeer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
Seer, Inc. has announced that it will report its financial results for the fourth quarter and full year of 2023 on February 29, 2024. The company, which specializes in proteomics technologies, is set to host a webcast of the financial results conference call. Seer's Proteograph Product Suite allows for efficient, deep proteomic analysis and is designed for research applications.
Read more →SEERSeer to Present at the J.P. Morgan 42nd Annual Health Care Conference
Seer, Inc. announced its participation in the J.P. Morgan 42nd Annual Health Care Conference in San Francisco on January 10, 2024. During the event, Seer’s management will present and conduct a Q&A session, allowing for direct engagement with investors. The company showcases its Proteograph Product Suite, which is designed for deep and unbiased proteomic analysis, although it is intended for research use only and not for diagnostic purposes.
Read more →SEERSeer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
Seer, Inc. announced that its management will participate in the Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York on November 16th. The company will present its innovative Proteograph Product Suite, which facilitates advanced proteomic analysis. A live webcast of the presentation will be available, along with an archived replay on Seer's website. This participation demonstrates Seer's commitment to showcasing their cutting-edge research products in the life sciences sector.
Read more →SEER▼ -5.2%on this newsshared move
Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500
Seer, Inc. has been awarded 'Proteomics Solution of the Year' in the 2023 BioTech Breakthrough Awards and has secured the #5 spot on the Deloitte Technology Fast 500. The CEO, Omid Farokhzad, emphasized the company's dedication to innovation following the launch of the Proteograph XT Assay Kit. These accolades recognize Seer's contributions to advancing proteomics and its potential impact on human health. The awards highlight the company's growth and commitment in the biotechnology sector.
Read more →SEERSeer Reports Third Quarter 2023 Financial Results
Seer, Inc. reported its financial results for the third quarter of 2023, highlighting a 5% year-over-year increase in revenue, totaling $4.2 million. The company expanded its global presence by forming partnerships with Danyel Biotech and GeneTiCA. Despite facing macroeconomic challenges, Seer received significant ISO certifications and observed increased customer engagement through more publications related to its Proteograph Product Suite. However, they also reported a net loss of $21.1 million and expect to meet the lower end of their revenue guidance for the year.
Read more →SEERSEER’S MV TECHNOLOGIES RECEIVES NEW CONTRACTS FOR $1.5MM AND INCREASES ANNUAL MEDIA SUPPLY CONTRACTS
Strategic Environmental & Energy Resources, Inc. (SEER) announced that its subsidiary, MV Technologies, secured new contracts worth approximately $1.5 million for H2S removal systems. These contracts, primarily from a large Northeastern utility company and a Canadian food processor, contribute to renewable natural gas projects aimed at reducing greenhouse gas emissions. Additionally, SEER is progressing on its environmental pilot projects in Saudi Arabia, moving towards sizable future orders as part of the Middle East Green Initiative.
Read more →SEERSeer Announces Addition of Panome Bio to Centers of Excellence (COE) Program
Seer Inc. has announced the integration of Panome Bio into its Centers of Excellence (COE) Program, enhancing their network of proteomics service providers. This partnership aims to leverage Panome Bio's expertise in metabolomics and its Next Generation Metabolomics technology to push forward research in biomarker discovery and drug development. The collaboration is expected to improve access to unbiased, deep proteomic insights, utilizing Seer's advanced Proteograph Product Suite and Proteograph XT Assay for enhanced research capabilities.
Read more →SEERSeer to Report Third Quarter 2023 Financial Results on November 7, 2023
Seer, Inc. (Nasdaq: SEER) announced that it will disclose its third quarter 2023 financial results on November 7, 2023, after market close. The company will host a conference call at 1:30 p.m. PT, which will be webcast for interested investors. Seer focuses on developing advanced solutions for proteomics, particularly through its Proteograph Product Suite, which allows for efficient and comprehensive proteomic analysis.
Read more →SEERSEER’S JOINT VENTURE PARTNER IN THE KINGDOM OF SAUDI ARABIA HAS BEEN AWARDED LARGE PILOT PROJECT INVOLVING SEVERAL OF THE LARGEST PUBLIC PARKS IN THE KINGDOM AS PART OF THE “GREEN RIYADH” PROJECT
SEER's joint venture partner, Modern Environmental Company, has secured a substantial pilot project in three major public parks in Saudi Arabia as part of the Green Riyadh initiative. Scheduled to commence in November 2023, the project aims to treat trees and shrubs using SEER's proprietary technologies, aligning with the country's Vision 2030 objectives for environmental sustainability. Successful completion may lead to long-term contracts for SEER to support various other projects across the Kingdom and the MENA region.
Read more →SEERSeer to Participate in Upcoming September Investor Conferences
Seer, Inc. has announced its participation in two upcoming investor conferences, including the Morgan Stanley Global Healthcare Conference and the Gilmartin Group Emerging Growth Company Showcase. These events highlight the company’s commitment to engaging with investors and its rising profile within the biopharma industry. Seer aims to demonstrate its innovative Proteograph Product Suite, which is designed for advanced proteomic analysis. Live webcasts of the conferences will be available, along with archived replays on the company's website.
Read more →SEERSeer Reports Second Quarter 2023 Financial Results
Seer, Inc. reported its second quarter 2023 financial results, with revenues reaching $4.0 million, an 11% increase compared to the prior year. Key developments included the launch of the Proteograph XT Assay Kit and the introduction of the Seer Technology Access Center. However, the company reported a net loss of $23.4 million, up from $22.8 million the previous year, and increased operating expenses driven by employee compensation. Seer also revised its full-year revenue expectations downward to between $16 million and $18 million.
Read more →SEERSeer to Present at the Canaccord Genuity 43rd Annual Growth Conference
Seer, Inc. announced its participation in the Canaccord Genuity 43rd Annual Growth Conference to be held in Boston on August 10th. The company's management will engage in a fireside chat, which will be accessible via live webcast. This event presents an opportunity for Seer to highlight its Proteograph Product Suite, which aims to revolutionize proteomic analysis. Interested parties can later access an archived version of the presentation via the company's website.
Read more →SEERSEER ANNOUNCES THE SALE OF ITS TEXAS-BASED PARAGON SOUTHWEST MEDICAL WASTE AFFILIATE TO PART OF THE AMLON GROUP
SEER has completed the sale of its Texas-based affiliate, Paragon Southwest Medical Waste, to Amlon Holdings, enabling a shift in focus towards international opportunities for its medical waste destruction technology. Following the closure of the transaction on June 30, PSMW will operate under the name Baytown Medical while holding an equity interest in Amlon Holdings. This acquisition facilitates a national rollout of medical waste treatment facilities, enhancing Amlon's capabilities. SEER retains a minority stake, allowing potential benefits as Paragon continues to expand with Amlon's resources.
Read more →SEERSeer to Report Second Quarter 2023 Financial Results on August 8, 2023
Seer, Inc. has announced that it will report its financial results for the second quarter of 2023 on August 8, 2023. The results will be shared after market close, followed by a conference call webcasting at 1:30 p.m. Pacific Time. Seer is noted for its development of the Proteograph Product Suite, which enables deep proteomic analysis.
Read more →SEERSEER ENTERS INTO MOU COVERING MULTIPLE LONG-TERM GREEN PROJECTS THROUGHOUT THE KINGDOM OF SAUDI ARABIA
SEER has entered into a Memorandum of Understanding with ECO Tadweer to establish a joint venture focused on environmental initiatives in Saudi Arabia. This collaboration aims to support the Kingdom's ambitious Middle East Green Initiative and various projects aimed at enhancing public health and environmental sustainability. SEER will provide its technologies, including organic fertilizers and biogas treatment, to contribute to achieving Saudi Arabia's goals for domestic agriculture and sustainability. Revenue generation from this initiative is expected to begin later in the year, with further project details anticipated in the near future.
Read more →SEERSeer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center
Seer, Inc. has announced an expanded collaboration with Thermo Fisher Scientific to enhance access to proteomics technologies through the establishment of the Seer Technology Access Center. This center will feature the new Proteograph XT Assay Kit alongside Thermo Fisher's Orbitrap Astral mass spectrometer, allowing researchers to conduct in-depth proteomic studies. The collaboration aims to optimize workflows and provide mass spectrometry services, ultimately facilitating population-scale research and improving insights into various health conditions. The Technology Access Center is set to launch in the summer of 2023.
Read more →SEER▲ +7.1%on this news· ran to +32% by day 3
Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies
Seer Inc. has launched the Proteograph XT Assay Kit, enhancing its Proteograph Product Suite with innovative proteomics capabilities. This new assay workflow allows researchers to process hundreds of samples per week while generating deep, unbiased proteomic data. Key features include high-resolution insights, increased throughput, and flexibility for various sample types. The company's proprietary engineered nanoparticles and accompanying analysis software aim to propel biological discovery in research labs globally.
Read more →SEERSeer Reports First Quarter 2023 Financial Results
Seer, Inc. reported strong financial results for the first quarter of 2023, achieving a revenue increase of 22% year-over-year to $4.1 million. The company noted continued growth in its installed base, with significant customer engagement and publications reflecting the effectiveness of its Proteograph Product Suite. However, Seer also reported a net loss of $24 million and an 18% increase in operating expenses compared to the previous year, highlighting financial pressures as it scales. The company anticipates a positive growth trajectory for the full year, projecting 48% to 61% revenue growth over 2022.
Read more →SEER▼ -5.4%on this news
Seer to Report First Quarter 2023 Financial Results on May 9, 2023
Seer, Inc. (Nasdaq: SEER) will announce its financial results for the first quarter of 2023 after market close on May 9, 2023. The company is known for its innovative Proteograph Product Suite aimed at enhancing proteomic analysis. A conference call will be held at 1:30 p.m. Pacific Time to discuss these results, which can be accessed live through Seer's website. The Proteograph technology is not intended for diagnostic use, underlining its focus on research applications.
Read more →SEERSeer’s Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression
Seer Inc. announced a study showcasing the efficacy of its Proteograph Product Suite in identifying biomarker associations between protein variants and non-small cell lung cancer (NSCLC) progression. Collaboration with Memorial Sloan Kettering Cancer Center highlighted four protein isoforms related to NSCLC, with findings suggesting that these protein variants may serve as novel therapeutic targets. Notably, these protein isoforms can be detected in readily accessible plasma samples, presenting new possibilities for liquid biopsy diagnostics. Future studies will be necessary to confirm these findings and their potential applications in clinical settings.
Read more →SEER▲ +7.7%on this news· ran to +39% by day 1
Seer Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Outlook
Seer, Inc. reported its financial results for the fourth quarter and full year of 2022, showcasing substantial growth with a revenue increase of 134% year-over-year. The company emphasized the success of its Proteograph Product Suite, which is significantly providing customers with deep protein coverage for biological insights. Despite the robust revenue growth, Seer noted an increase in operational losses and expenses, leading to a net loss of $93 million for the entire year. The company is optimistic about 2023, forecasting a revenue range of $23 million to $25 million, reflecting continued growth in its commercial activities.
Read more →SEER▼ -11.3%on this news
Seer to Present at the Cowen 43rd Annual Health Care Conference
Seer, Inc. has announced its participation in the Cowen 43rd Annual Health Care Conference set to take place on March 8th, 2023. The company's management will engage in a fireside chat and Q&A session, emphasizing its pioneering work in proteomics. Seer's Proteograph Product Suite, designed for efficient and unbiased proteomic analysis, exemplifies its innovative approach in the life sciences sector. The session will be accessible through a live webcast and archived on the company’s website.
Read more →SEERSEER’S MV TECHNOLOGIES RECEIVES CONTRACTS FOR MORE THAN $2MM
SEER's subsidiary, MV Technologies, has received multiple contracts exceeding $2 million for the installation of its H2S removal systems in biogas projects across the US and Canada. Additionally, MV has a significant number of project bids outstanding, valued at approximately $22 million, indicating strong demand for its technology. However, the company has also suspended operations at its Texas facility due to logistics and cost challenges. SEER remains optimistic about future growth opportunities driven by renewable energy technologies.
Read more →SEERSeer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
Seer, Inc. is set to announce its financial results for the fourth quarter and full year of 2022 on March 2, 2023. The announcement will follow market close, and a conference call will be webcast starting at 1:30 p.m. PT. The company is known for its Proteograph Product Suite, which aims to revolutionize proteomic analysis in laboratories.
Read more →SEERSEER’S TEXAS OPERATING PARTNER COMPLETES ITS FACILITY RELOCATION AND IMPROVES BOTTOM LINE RESULTS WITH PLANS TO COMMENCE ROLL OUT OF MULTIPLE US FACILITIES WITH OTHER LARGE MEDICAL WASTE BUSINESSES IN EARLY 2023
Strategic Environmental & Energy Resources, Inc. (SEER) announced that its operating partner, Paragon Southwest Medical Waste (PSMW), has successfully relocated to an expanded facility in Baytown, Texas. This move is part of a market consolidation plan and is expected to yield significant cost savings. The facility is now running near capacity and plans are in place to treat additional waste types and expand operations into new regions, including potential international markets. SEER aims to fully optimize its operations throughout 2023.
Read more →SEER▼ -10.3%on this news
Seer to Present at the J.P. Morgan 41st Annual Health Care Conference
REDWOOD CITY, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conferenc
Read more →SEERSeer’s Proteomics Platform Named as Top 10 Innovation in 2022 by The Scientist
REDWOOD CITY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the Proteograph Product Suite has been named one of The Scientist's 2022 Top 10 Innovations, an
Read more →SEER▼ -8.5%on this news· ran to +22% by day 3
Seer Reports Third Quarter 2022 Financial Results
REDWOOD CITY, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2022. “During the third quarter, we con
Read more →SEERSeer to Report Third Quarter 2022 Financial Results on November 8, 2022
REDWOOD CITY, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the third quarter of 2022 on Tuesday, November 8, 2022. Compan
Read more →SEERSeer to Participate in the Morgan Stanley Global Healthcare Conference
REDWOOD CITY, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference
Read more →SEERSeer Announces Publication of Seminal Study Demonstrating the Power of Engineered Nano-Bio Interactions to Enable Deep Access to the Proteome
REDWOOD CITY, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced the publication of a study demonstrating the performance of the technology underlying the Proteograph™ Product Suite for deep, unbiased, precise, scalable proteomics. The paper, enti
Read more →SEER▼ -7.8%on this news· ran to +19% by day 1
Seer Reports Second Quarter 2022 Financial Results
REDWOOD CITY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2022. “We are building on a strong start to
Read more →SEER▲ +13.4%on this news· ran to +25% by day 3
Seer Launches First-of-its-kind Proteogenomics Workflow to Link Genetic Changes with Protein Variants with Proteograph™ Analysis Suite 2.0
REDWOOD CITY, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced a new Proteogenomics Workflow that integrates deep, unbiased proteomics with genomics, powered by th
Read more →SEER▲ +13.4%on this news· ran to +25% by day 3
SEER ENTERS INTO AN AGREEMENT WITH ITS TEXAS OPERATING PARTNER TO CONSOLIDATE THE NORTH AMERICAN MEDICAL WASTE MARKET AND PLANS TO COMMENCE ROLL OUT OF WEST COAST FACILITIES
SEER and its Texas JV partner, Paragon Southwest Medical Waste, LLC (“PSMW”), have entered into an agreement to consolidate the North American medical waste market under PSMW and commence efforts to grow the business beyond the current Texas territory and roll out their plans to
Read more →SEER▼ -5.9%on this news
Seer to Report Second Quarter 2022 Financial Results on August 9, 2022
REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the second quarter of 2022 on Tuesday, August 9, 2022. Company
Read more →SEER▲ +6%on this news
Seer Reports First Quarter 2022 Financial Results
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2022. “We had a strong start to the year as
Read more →SEERSeer to Present at the BofA Securities 2022 Healthcare Conference
REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference
Read more →SEERSeer to Report First Quarter Financial Results on May 4, 2022
REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the first quarter of 2022 on Wednesday, May 4, 2022. Company m
Read more →SEER▲ +7.9%on this news· ran to +19% by day 1
Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer
REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thoma
Read more →SEERSeer Announces Publication of Seminal Study Demonstrating Superior Performance of Technology Platform for Deep, Unbiased, Precise, Scalable Proteomics in the Proceedings of the National Academy of Sciences
Published results highlight simultaneous superior performance across depth, precision, and throughput versus conventional plasma proteomics workflows REDWOOD CITY, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced the publication of a study dem
Read more →SEERSeer Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Outlook
REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2021. “This has been a mo
Read more →SEERSeer to Present at the Cowen 42nd Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating virtually in the upcoming Cowen 42nd Annual Health Care Conf
Read more →SEER▲ +10.4%on this news
Seer to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2021
REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Mon
Read more →SEERSEER’S MV TECHNOLOGIES RECEIVES APPROXIMATELY $1.75MM OF BIOGAS SYSTEM CONTRACTS FOR FOUR US RENEWABLE NATURAL GAS PROJECTS
MV Technologies contracts to design and install its H2S removal systems for four new biogas/RNG system in the US and has outstanding bids valued at approximately $3.5MM for additional systems worldwide. BROOMFIELD, CO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Strategic Environmental &
Read more →SEERSeer, Discovery Life Sciences and SCIEX Announce First-Of-Its-Kind Proteogenomics Consortium for Large-Scale Studies
REDWOOD CITY, Calif. and HUNTSVILLE, Ala. and FRAMINGHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics; SCIEX, a global leader in life science analytical technologies; and Disco
Read more →SEERSeer Announces Broad Commercial Release of the Proteograph™ Product Suite and Launches Centers of Excellence Program
REDWOOD CITY, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced Broad Commercial Release of its Proteograph Product Suite and the launch of its Centers of Excellenc
Read more →SEERSeer to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference. S
Read more →SEER▼ -8.6%on this newsshared move
SEER ALERT: Bragar Eagel & Squire, P.C. is Investigating Seer, Inc. on Behalf of SEER Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Seer, Inc. (“Seer” or the “Company”) (NASDAQ: SEER) on behalf of Seer stockholders. Our investigation concerns w
Read more →SEER▼ -5.9%on this news
Seer Appoints Meeta Gulyani to its Board of Directors
REDWOOD CITY, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Meeta Gulyani to serve on its Board of Directors. Ms. Gulyani is currently Execut
Read more →SEER▼ -9.3%on this news
SEER INVESTIGATION: Block & Leviton Is Investigating Seer Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Seer, Inc. (NASDAQ: SEER) for potential securities law violations. Investors who have lost money in their Seer investment should contact the firm to learn more about how they might recover those losses. Fo
Read more →SEER▼ -9.3%on this news
Seer to Participate in the Piper Sandler Virtual Healthcare Conference
REDWOOD CITY, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference.
Read more →SEERSeer Reports Third Quarter 2021 Financial Results
REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2021. “We continued to make outstanding
Read more →SEERSeer Appoints Rachel Haurwitz, Ph.D., to its Board of Directors
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Rachel Haurwitz, Ph.D. to serve on its Board of Directors, effective November 8,
Read more →SEER▼ -5%on this newsshared move
(SEER) Alert: Did You Lose Money on Your Seer Investment? Contact Johnson Fistel Regarding Investigation
SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Seer, Inc. (NASDAQ: SEER) for violations of federal securities laws. On November 4, 2021, Bear Cave, a short seller, published a report stating
Read more →SEER▲ +5.6%on this news
Seer to Report Third Quarter Financial Results on November 9, 2021
REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the third quarter 2021 after market close on Tuesday, November
Read more →SEER▲ +8.9%on this news
Seer to Present at the Morgan Stanley Global Healthcare Conference
REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference.
Read more →SEERSeer Reports Second Quarter 2021 Financial Results
REDWOOD CITY, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2021. “I am incredibly proud of our team an
Read more →SEERSeer Bio Partners with Enlight Medical to Commercialize the Proteograph™ Product Suite in China
REDWOOD CITY, Calif. and BEIJING, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has signed an exclusive distribution agreement with Enlight Medical, a leading compan
Read more →SEERSeer to Report Second Quarter Financial Results on August 12, 2021
REDWOOD CITY, Calif., July 13, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the second quarter 2021 after market close on Thursday, August
Read more →SEERSeer Reports First Quarter 2021 Financial Results
Second Phase of Commercialization Advances with the Addition of Multiple Limited Release Customers REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported f
Read more →SEERSeer to Present at the BofA Securities 2021 Healthcare Conference
REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating virtually in the upcoming BofA Securities 2021 Healthcare Conference. See
Read more →SEERSEER’S MV TECHNOLOGIES RECEIVES MORE THAN $1.6MM OF BIOGAS SYSTEM CONTRACTS FOR THREE NORTH AMERICAN RENEWABLE NATURAL GAS PROJECTS
MV Technologies contracts to design and install its H2S removal systems for three new biogas/RNG system in the US and Canada. BROOMFIELD, CO, April 21, 2021 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environmental, re
Read more →SEERSeer to Report First Quarter Financial Results on May 10, 2021
REDWOOD CITY, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the first quarter 2021 after market close on Monday, May 10,
Read more →SEERSeer and SCIEX Sign Commercial Agreement to Offer End-to-End Unbiased Proteomics Solutions
REDWOOD CITY, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Seer (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today that they have signed a non-exclusive commercial agreement with SCIEX, a global leader in life science a
Read more →SEERSeer Reports Fourth Quarter and Full Year 2020 Financial Results and Fuels Commercial Progress in 2021 with New Collaborators and Partnerships
REDWOOD CITY, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the quarter and full year ended December 31, 2020. “I am extremely proud of
Read more →SEERSeer to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021
REDWOOD CITY, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the fourth quarter and full year 2020 after market close on
Read more →SEERSeer to Present at the Cowen 41st Annual Healthcare Conference
REDWOOD CITY, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating in the upcoming Cowen 41st Annual Healthcare Conference. Seer’s manageme
Read more →SEERSeer Appoints Deep Nishar and Mostafa Ronaghi, Ph.D. to its Board of Directors
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Deep Nishar and Mostafa Ronaghi, Ph.D. to serve on its Board of Directors, effect
Read more →SEERDocument Ex. 99.1 Seer Appoints Deep Nishar and Mostafa Ronaghi, Ph.D. to its Board of Directors Company adds two directors with experience in building and growing transformative companies Redwood City, CA
Seer Appoints Deep Nishar and Mostafa Ronaghi, Ph.D. to its Board of Directors Company adds two directors with experience in building and growing transformative companies Redwood City, CA, February 17, 2021 - Seer, Inc., (Nasdaq SEER), a life sciences company commercializing a
Read more →SEERSeer Announces Closing of Public Offering of Common Stock
REDWOOD CITY, Calif. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the closing of an underwritten public offering of 3,750,000 shares of Class A common stock at a public offering p
Read more →SEERSeer Announces Pricing of Upsized Public Offering of Common Stock
REDWOOD CITY, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the pricing of an underwritten public offering of 3,750,000 shares of Class A common stock (1,650,000 of which are
Read more →SEERSeer Announces Proposed Public Offering of Common Stock Redwood City, Calif. (
Seer Announces Proposed Public Offering of Common Stock Redwood City, Calif. (January 25, 2021) - Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the commencement of a proposed underwritten public offering of 3,500,00
Read more →SEERSeer and Bruker Sign Commercial Agreement to Expand Market for Unbiased, Deep Proteomics
REDWOOD CITY, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Seer (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today that they have signed a non-exclusive commercial agreement with Bruker Corporation, one of the world’s le
Read more →SEERSeer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Proteomics
REDWOOD CITY, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Seer (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today that it has signed a non-exclusive commercial agreement with Thermo Fisher Scientific, a world leader in
Read more →SEERSEER SIGNS MOU WITH US-BASED BWAB INC., AND ITS EUROPEAN-BASED AFFILIATES FOR INTERNATIONAL ROLLOUT OF SEER’S TECHNOLOGIES
The parties are exploring options to form a new entity, SEER Corp. International, to leverage BWAB’s funding capabilities, global connections and key personnel in order to monetize SEER’s existing IP portfolio internationally, as well as identify strategic acquisitions of other v
Read more →SEERSeer to Present at the 39th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced the company will be parti
Read more →SEERSeer Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares Redwood City, Calif. (
Seer Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares Redwood City, Calif. (December 8, 2020) - Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbias
Read more →SEERSeer Announces Pricing of Initial Public Offering
REDWOOD CITY, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced the pricing of its initial public offeri
Read more →SEERSeer Announces Spin Out of PrognomIQ with $55 Million Initial Financing
-- PrognomIQ to develop multi-omics tests leveraging Seer’s Proteograph product -- -- Seer to retain minority ownership in PrognomIQ -- REDWOOD CITY, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcom
Read more →SEERSeer Appoints Catherine Friedman to its Board of Directors
REDWOOD CITY, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced that it has appointed Catherine Friedma
Read more →SEERSeer Announces $55M Financing Led by Fidelity Management and Research Company
REDWOOD CITY, Calif., July 22, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on empowering exceptional scientific outcomes through the power of rapid, deep, unbiased proteomics information, today announced that it has raised $55 million in a new funding rou
Read more →SEERSeer Announces Publication in Nature Communications Demonstrating Performance, Scalability and Utility of its Platform Technology for Deep, Unbiased Proteomics
Published results reveal differentiated ability of proprietary, engineered nanoparticle technology to enable large-scale proteomics studies to: Provide new insights into dynamic nature of the proteome Lead to discovery of potentially novel biomarkers Complement large-scale gen
Read more →SEERSeer Announces Appointment of David R. Horn as Chief Financial Officer
-- Morgan Stanley executive brings extensive life sciences sector strategic and financial expertise to pioneering proteomics company -- REDWOOD CITY, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on commercializing proprietary solutions to
Read more →SEERSeer Announces Appointment of Omead Ostadan as President and Chief Operating Officer
REDWOOD CITY, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on commercializing a proprietary solution that uniquely enables efficient, unbiased, and deep surveying of the proteome, announced today that Omead Ostadan will join as the company’
Read more →SEERSEER’s Newly Formed Division, Pellechar, Receives $1 Million in Equity Capital and Prepares to Enter Multi-Billion Dollar Fertilizer Market
Company’s Subsidiary, Pellechar, Has Secured Production of its Proprietary Combination Pellet and is in Final Stages of Completing OMRI Certification and Other Regulatory Requirements GOLDEN, Colo., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, In
Read more →SEERSEER Awarded $1.3 Million Contract to Install Large Landfill Gas System
Company’s Subsidiary, MV Technologies, Receives $1.3 Million Contract to Install an LFG System; Continues to Grow Recurring Revenue Base GOLDEN, Colo., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environm
Read more →SEERSEER to Reschedule Third Quarter Financial Results and Operational Update Conference Call to December 2018
GOLDEN, Colo., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environmental, renewable fuels and industrial waste stream management services, has announced that it is postponing its previously scheduled confe
Read more →SEERSEER Reports Third Quarter 2018 Financial Results
Third Quarter 2018 Conference Call Scheduled for November 29, 2018 at 4:30 p.m. ET GOLDEN, Colo., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environmental, renewable fuels and industrial waste stream man
Read more →SEERSEER to Host Third Quarter Financial Results and Operational Update Conference Call on Thursday, November 29, 2018 at 4:30 p.m. ET
GOLDEN, Colo., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environmental, renewable fuels and industrial waste stream management services, will hold a conference call on Thursday, November 29, 2018 at 4:3
Read more →SEERSEER Appoints Dr. Simon Tang as Vice-Chairman of the Board and Chairman of Newly Formed SEER Asia-Pacific Subsidiary
Company’s New Subsidiary to Facilitate Investment by Strategic Partners and Rollout of SEER’s Patented Technologies in the Asia-Pacific Region GOLDEN, Colo., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of en
Read more →SEERSEER Reports Second Quarter 2018 Financial Results
Second Quarter 2018 Conference Call Scheduled for Wednesday, August 15, 2018 at 11:30 a.m. ET GOLDEN, Colo., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environmental, renewable fuels and industrial waste
Read more →SEERSEER’s Service Division Receives First Order for Over $1 Million of Biochar Now Production Equipment
Increased Biochar Demand Expected to Drive New Manufacturing Revenue and Related Service Projects to REGS GOLDEN, Colo., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environmental, renewable fuels and indu
Read more →SEERSEER Appoints Scott Yenzer to its Board of Directors
GOLDEN, Colo., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environmental, renewable fuels and industrial waste stream management services, has appointed Scott Yenzer, corporate development officer of Black
Read more →SEERSEER to Host Second Quarter Financial Results Conference Call on Wednesday, August 15, 2018 at 11:30 a.m. ET
GOLDEN, Colo., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), a provider of environmental, renewable fuels and industrial waste stream management services, will hold a conference call on Wednesday, August 15, 2018 at 11:30
Read more →SEERSEER Provides Operational Update on Industrial Cleaning and Environmental Technology Solutions Divisions
GOLDEN, Colo., June 26, 2018 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB:SENR), a provider of environmental, renewable fuels and industrial waste stream management services, has provided the following operational update with its industrial c
Read more →SEERSEER Reports First Quarter 2018 Financial Results
First Quarter 2018 Highlighted by Significant Reduction in Net Cash Used in Operations and Start-Up of Paragon Southwest Medical Waste in Anahuac, Texas First Quarter 2018 Conference Call Scheduled for Early June Post Major Pending Operational Milestone Achievements GOLDEN, Col
Read more →Competitive Position
How SEER ranks across every disease it competes inCompetitive Position is a premium feature
See how SEER ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial